Skip to main content

Advertisement

SpringerLink
Log in

Dystonia and leveraging oral pharmacotherapy

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Dystonia is a clinically diverse disorder, characterized by sustained or intermittent muscle contractions causing abnormal and often repetitive movements and/or postures. Accurate clinical diagnosis is tantamount to effective dystonia management. Current guidelines in the treatments of dystonia, including oral therapy, are prescribed to improve symptoms and to restore functional capacity. Identifying treatable causes from co-existing phenomenologies is relevant to provide the most optimal and disease-specific medications. In other forms of dystonia, genetic factors may affect outcome. Moreover, proper selection of patients, early initiation of medications and customized drug titration are keys to increasing the chances of success when using oral therapies for dystonia. Treatment of dystonia primarily involves agents that target dopamine and acetylcholine receptors. Other drugs used include benzodiazepines, baclofen, antiepileptics, some antipsychotics drugs and antihistamine, with different levels of evidence of effectiveness. Unfortunately, most of the widely used drugs have low levels of evidence and are primarily based on anecdotal experiences. Finally, other adjunctive therapeutic strategies are often necessary to complement oral therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adler A, Peselow E, Rotrosen J, Duncan E, Angrist B (1993) Brief reports vitamin. Biol Psychiatry 9:1405–1407

    Google Scholar 

  • Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M et al (1998) Long-term treatment effects of vitamin e for tardive dyskinesia. Biol Psychiatry 19:134–138

    Google Scholar 

  • Albanese MA, Barnes MP, Bhatia KP, Fernandez-alvarez E (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 26:433–444

    Article  Google Scholar 

  • Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G et al (2009) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 1:5–18

    Google Scholar 

  • Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5–17

    Article  CAS  PubMed  Google Scholar 

  • Alfradique-dunham I, Jankovic J, Alfradique-Dunham I, Jankovic J (2017) Expert opinion on orphan drugs available treatment options for dystonia available treatment options for dystonia. Expert Opin Orphan Drugs [Internet] 6:1–10. https://doi.org/10.1080/21678707.2017.1366309

    Article  CAS  Google Scholar 

  • Anca MH, Zaccai TF, Badarna S, Lozano AM, Lang AE, Giladi N (2003) Natural history of oppenheim ’ s dystonia (DYT1) in Israel. J Child Neurol 18(5):325–330

    Article  PubMed  Google Scholar 

  • Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia ( AIM-TD ): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psyc 366(17):1–10

    Google Scholar 

  • Ankenman R, Salvatore MF (2007) Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J NeuropsycClinNeurosci 19(1):65–69

    CAS  Google Scholar 

  • Ankenman R, Salvatore MF, Burke RE, Fahn S, Marsden CD et al (2014) Treatment of dystonia. MovDisord [Internet] 24(4):724–732. https://doi.org/10.1186/s40734-016-0047-6

    Article  Google Scholar 

  • Ann J, Torres KL, Rosales RL (2017) Nonmotor symptoms in dystonia. Internat Rev Neurobiol 134:1335–1371

    Article  Google Scholar 

  • Badillo SPJ, Jamora RDG (2019) Zolpidem for the treatment of dystonia. Front Neurol 10:1–7

    Article  Google Scholar 

  • Batla A (2012) Neurology DM. Treat Focal Dystonia 2:213–229

    Google Scholar 

  • Bhidayasiri R (2006) Dystonia: genetics and treatment update. Neurologist 12(2):74–85

    Article  PubMed  Google Scholar 

  • Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S (2018) Journal of the neurological sciences updating the recommendations for treatment of tardive syndromes : a systematic review of new evidence and practical treatment algorithm. J NeurolSci 389:67–75. https://doi.org/10.1016/j.jns.2018.02.010

    Article  Google Scholar 

  • Brien CFO, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D et al (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia : a randomized, double-blind, placebo-controlled study. Move Dis 30(12):1681–1687

    Article  Google Scholar 

  • Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36(2):160–164

    Article  CAS  PubMed  Google Scholar 

  • Cai C, Shi W, Zeng Z, Zhang M, Ling C, Chen L et al (2013) GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. PLoS ONE 8(6):4–8

    Article  Google Scholar 

  • Comella CL (2015) Dystonia: then and now. Park RelatDisord 46:S66–S69. https://doi.org/10.1016/j.parkreldis.2017.06.025

    Article  Google Scholar 

  • De Silva R, Greenfield J, Cook A, Bonney H, Vallortigara J, Hunt B et al (2019) Guidelines on the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis 14(1):1–10

    Article  Google Scholar 

  • Decker BL, Davis J, Janowsky DS, El Yousef K, Sekerke HJ (1971) Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med 285:860

    Article  CAS  PubMed  Google Scholar 

  • Delnooz CCS, Van De WBPC (2012) Current and future medical treatment in primary dystonia. TheraAdvNeurol Dis 12:221–240

    Google Scholar 

  • Dufresne RL, Becker RE, Mastrati P (1978) Diazepam in tardive dyskinesia. Move Dis 17:523–527

    Google Scholar 

  • Fahn S (1987) Systemic therapy of dystonia. Can J NeurolSci 14(3):528–532

    Article  CAS  Google Scholar 

  • Fernandez HH, Friedman JH (1999) The role of atypical antipsychotics in the treatment of movement disorders. Move Dis Soc 11(6):467–483

    CAS  Google Scholar 

  • Fernandez HH, Meltzer HY, Woods SW, Bega D, Ledoux MS, Davis C et al (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia The ARM-TD study. Neurology 7:2003–2010

    Article  Google Scholar 

  • Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V et al (2012) Sepiapterin reductase deficiency : a treatable mimic of cerebral palsy. Ann Neurol 123:520–530

    Article  Google Scholar 

  • Frucht SJ (2017) Dystonic storm : a practical clinical and video review. Move Dis 2:1–8

    Google Scholar 

  • Fung VSC, Hallett M, Jankovic J, Jinnah HA, Klein C (2013) Phenomenology and classification of dystonia: a consensus update. MovDisord 28(7):863–873. https://doi.org/10.1002/mds.25475

    Article  Google Scholar 

  • Gilbert GJ, Petersburg S (2015) The medical treatment of spasmodic torticollis. Eur J Neurol 15:7–10

    Google Scholar 

  • Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M (1985) The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87(4):480–483

    Article  CAS  PubMed  Google Scholar 

  • Gn S (2017) Case report management of oromandibulardystonia : a case report and literature update. Movement 17:109–234

    Google Scholar 

  • Greene P (1992) Baclofen in the treatment of dystonia. ClinNeuropharmacol 15(4):276–288

    CAS  Google Scholar 

  • Greene P, Shale H, Fahn S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. J Move Dis Soc 3(1):46–60

    Article  CAS  Google Scholar 

  • Guay DRP (2010) Tetrabenazine a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J GeriatrPharmacother [Internet] 8(4):331–373. https://doi.org/10.1016/j.amjopharm.2010.08.006

    Article  CAS  Google Scholar 

  • Hauser RA, Factor SA, Marder SR, Knesevich MA (2017) KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psyc 2:10–34

    Google Scholar 

  • Jankovic J (1981) I reatment of hyperkmeac movement disorders with tetrabenazine : a double-blind crossover study. Ann Neurol 1:41–47

    Google Scholar 

  • Jankovic J (2006) Treatment of dystonia. Lancet Neurol 5(10):864–872

    Article  CAS  PubMed  Google Scholar 

  • Jinnah HA (2015) Diagnosis and treatment of dystonia. NeurolClin NA 33(1):77–100. https://doi.org/10.1016/j.ncl.2014.09.002

    Article  CAS  Google Scholar 

  • Jinnah HA (2019) TheDystonias. Contin Lifelong Learn Neurol 25(4):976–1000

    Article  CAS  Google Scholar 

  • Josiassen BRC, Kane JM, Liang GS, Burke J, Brien CFO (2007) Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia. Mood Dis 47(3):8

    Google Scholar 

  • Karp BI, Goldstein SR, Chen R, Samii A, Bara-jimenez W, Hallett M (1999) An open trial of clozapine for dystonia. Move Dis Soc 14(4):652–657

    Article  CAS  Google Scholar 

  • Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia A long-term follow-up study of 107 cases. Brain J Neurol 1998:2053–2066

    Article  Google Scholar 

  • Lizarraga KJ, Al-shorafat D, Fox S (2019) Update on current and emerging therapies for dystonia. Neurodegen dis manag 9:135–147

    Article  Google Scholar 

  • Lubarr N, Bressman S (2011) Treatment of generalized dystonia. Move Dis 26(6):274–289

    Google Scholar 

  • Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, Ledoux MS (2014) Treatment of myoclonus-dystonia syndrome with tetrabenazine. Park RelatDisord 20(12):1423–1426. https://doi.org/10.1016/j.parkreldis.2014.09.029

    Article  Google Scholar 

  • Ma RAH, Unit G (2004) Case report Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Develop Med Child Neurol 4:710–712

    Google Scholar 

  • Margolius A, Fernandez HH (2019) Parkinsonism and related disorders current treatment of tardive dyskinesia. Park RelatDisord [Internet] 59:155–160. https://doi.org/10.1016/j.parkreldis.2018.12.022

    Article  Google Scholar 

  • Mariotti P, Fasano A, Contarino MF, Della MG, Piastra M, Genovese O et al (2007) Management of status dystonicus: our experience and review of the literature. Move Dis 22(7):963–968

    Article  Google Scholar 

  • Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, Tijssen MA, van Harten PN (2017) Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curaçao extrapyramidal syndromes study XII. J Clin Psychiatry 78(3):e279–e285

    Article  PubMed  Google Scholar 

  • Miyazaki Y, Sako W, Asanuma K, Izumi Y, Miki T, Kaji R (2012) Efficacy of zolpidem for dystonia : a study among different subtypes. Front Neurol 3:1–58

    Google Scholar 

  • Miyazaki Y, Koizumi H, Miyamoto R, Kawarai T, Kaji R (2015) Treatment of isolated dystonia with zolpidem. Move Dis ClinPract 8:309–311

    Google Scholar 

  • Papapetropoulos S, Singer C (2006) Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol 253(4):535–536

    Article  PubMed  Google Scholar 

  • Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. ClinNeuropharmacol 33(6):271–275

    CAS  Google Scholar 

  • Rice J, Waugh Mary-Clare MC (2009) Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol 24(2):176–182

    Article  PubMed  Google Scholar 

  • Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L et al (2007) Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 22(5):530–537

    Article  PubMed  Google Scholar 

  • Schiller A, Wevers RA, Steenbergen GCH, Blau N, Jung HH (2004) Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 4:1524–1527

    Article  Google Scholar 

  • Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56(1):75–80

    Article  CAS  PubMed  Google Scholar 

  • Snoek JW, Zwarts MJ, Van WTW, Van HJJ, Der KV, Speelman JD (1996) Botulinurn toxin versus trihexyphenidyl in cervical dystonia. Neurology 6:19

    Google Scholar 

  • Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA (2005) Levetiracetam for the treatment of generalized dystonia. Park Related Disord 11:469–471

    Article  Google Scholar 

  • Termsarasab P, Thammongkolchai T, Frucht SJ (2016) Medical treatment of dystonia. J Clin Mov Disord [Internet]. 3(1):19. Available from: http://clinicalmovementdisorders.biomedcentral.com/articles/https://doi.org/10.1186/s40734-016-0047-6

  • Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 147(4):445–451

    Article  CAS  PubMed  Google Scholar 

  • Thenganatt MA, Jankovic J (2014) Treatment of dystonia. Neurotherapeutics 11(1):139–152

    Article  CAS  PubMed  Google Scholar 

  • Trosch RM, Friedman JH, Lannon C, Smith D, Seeberger LC, Brien CFO et al (1998) Clozapine use in parkinson’s disease : a retrospective analysis of a large multicentered clinical experience. Move Dis 13(3):377–382

    Article  CAS  Google Scholar 

  • Vanasse M, Chouinard S (2010) A case of secondary dystonia responding to levodopa. J Child Neurol 25(6):780–781

    Article  PubMed  Google Scholar 

  • Victorri-vigneau C, Dailly E, Veyrac G, Jolliet P (2007) Evidence of zolpidem abuse and dependence : results of the french centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J ClinPharmacol 64(2):198–209

    Google Scholar 

  • Zesiewicz TA, Louis ED (2004) Substantial improvement in a meige’s syndrome patient with levetiracetam treatment. Movement Dis 19(12):2002–2005

    Article  Google Scholar 

  • Zheng W, Xiang YQ, Ng CH, Ungvari GS, Chiu HF, Xiang YT (2016) Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry 49(3):107–111

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Movement Disorders Section, Center for Neurological Restoration Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

    Michelle Ann C. Sy

  2. Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

    Hubert H. Fernandez

Authors
  1. Michelle Ann C. Sy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hubert H. Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle Ann C. Sy.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sy, M.A.C., Fernandez, H.H. Dystonia and leveraging oral pharmacotherapy. J Neural Transm 128, 521–529 (2021). https://doi.org/10.1007/s00702-021-02339-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-021-02339-7

Keywords

Search

Navigation